Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL566640 | 0.99 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL566070 | 0.99 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL567085 | 0.98 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL567027 | 0.98 | TLR7 (0.94) | TLR7TLR8 | |
| SCHEMBL565794 | 0.97 | TLR7 (0.98) | TLR7TLR8 | |
| SCHEMBL567011 | 0.97 | TLR7 (0.98) | TLR7TLR8 | |
| SCHEMBL565975 | 0.97 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL567100 | 0.97 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL566753 | 0.96 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL567076 | 0.96 | TLR7 (1.00) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067413-B2 | 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7 ) modulators | ASTRAZENECA AB (SE) | 2011-11-29 | — | — | US | claimed |
| US-20100130491-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7 ) MODULATORS | Sumitomo Pharma Co., Ltd. (JP) | 2010-05-27 | — | — | US | claimed |
| EP-2132209-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7 ) MODULATORS | AstraZeneca AB (SE) | 2009-12-16 | — | — | EP | claimed |
| WO-2008114008-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7 ) MODULATORS | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | WO | claimed |
| US-20190038631-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2019-02-07 | — | — | US | disclosed |
| US-20190038631-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2019-02-07 | — | — | US | disclosed |
| US-10117873-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2018-11-06 | — | — | US | disclosed |
| EP-3336089-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GlaxoSmithKline LLC (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-3336089-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GlaxoSmithKline LLC (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20180117048-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2018-05-03 | — | — | US | disclosed |
| US-20180117048-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2018-05-03 | — | — | US | disclosed |
| US-9877968-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2018-01-30 | — | — | US | disclosed |
| US-20100130491-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7 ) MODULATORS | Sumitomo Pharma Co., Ltd. (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100130491-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7 ) MODULATORS | Sumitomo Pharma Co., Ltd. (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100075995-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075995-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075995-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2010018133-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-18 | — | — | WO | disclosed |
| EP-2132209-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7 ) MODULATORS | AstraZeneca AB (SE) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008114008-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7 ) MODULATORS | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038631-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | IFNG, IFNAR1, IRF3 | TLR7 7/4885TLR8 15/4885 |
| US-10117873-B2 | 6-amino-purin-8-one compounds | IFNG, IFNAR1, IRF3 | TLR7 7/4885TLR8 15/4885 |
| US-20180117048-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | IFNG, IFNAR1, IRF3 | TLR7 7/4885TLR8 15/4885 |
| US-20100130491-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7 ) MODULATORS | TLR9, TLR7, TLR8 | TLR7 2/4885TLR8 3/4885 |
| US-20100075995-A1 | COMPOUNDS | IFNG, IRF3, IFNAR1 | TLR7 8/4885TLR8 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.